Lanifibranor is under clinical development by Inventiva and currently in Phase II for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lanifibranor LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lanifibranor overview
Lanifibranor is under development for the treatment of non alcoholic fatty liver disease (NAFLD), type 2 diabetes, liver fibrosis, prehapetic portal hypertension, non-alcoholic steatohepatitis. It is administered through oral route in the form of tablet. It is a new chemical entity. The drug candidate targets (PPAR) peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-gamma and PPAR -delta receptors). It is under development for type 2 diabetes. It was also under development for the treatment of diabetes and systemic sclerosis. It was also under development for the treatment of idiopathic pulmonary fibrosis, compensated cirrhosisz.
Inventiva overview
Inventiva is a biopharmaceutical company The company discovers and develops therapies for fibrosis, oncology and lysosomal storage disorders. Its pipeline products include lanifibranor for non-alcoholic steatohepatitis, odiparcil for mucopolysaccharidosis, ABBV-157 for moderate to severe psoriasis, hippo for non-small cell lung Cancer and mesothelioma, and GEV for idiopathic pulmonary fibrosis. It develops compounds that target nuclear receptors, transcription factors and epigenetic modulation. The company has two innovative clinical programs, NATIVE and IMPROVES. It conducts its drug discovery research and development in partnership with various medical organizations such as AbbVie, Abbott, Solvay, and Fournier. Inventiva is headquartered in Daix, France.
For a complete picture of Lanifibranor’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
